PROteolysis TArgeting Chimeras (PROTACs) are receiving increasing attention as a new therapeutic modality, as was recently underscored by the first PROTAC, ARV-110, to enter clinical trials . PROTACs are comprised of a protein target binding moiety, a linker and an E3 ubiquitin ligase binder . Upon binding, the PROTAC induces the formation of a ternary complex between the target and E3 ligase resulting in the ubiquitination and degradation of the target. Compared to traditional inhibition of the target protein, targeted degradation has several important advantages, including the elimination of all levels of protein function, enhanced selectivity , longer duration of action due to the need to resynthesize the target , and degradation by sub-stoichiometric amounts of PROTAC .